Pharma solutions
Lipidor develops pharmaceuticals for skin with unique lipid based formulation opportunities for global pharma companies. Our proprietary delivery platform and expertise help pharma companies launch innovative, patient-friendly skin treatments, in record time.
Introduction
Our innovative and flexible delivery system AKVANO® brings a number of tangible benefits for pharmaceutical companies and patients alike.
Our focus is to reformulate existing generika to new, innovative candidates using our proprietary delivery platform AKVANO®. Reformulating existing substances enables a faster track through clinical trials to regulatory approval – and together with our clients – commercial launch.
The flexibility of the AKVANO® platform has enabled us to successfully incorporate more than 60 structurally very different active pharmaceutical ingredients, used in many different therapeutic applications. Applications such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anaesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema and anti-migraine.
Ease of use
AKVANO® formulations provide excellent cosmetic qualities, are quick and simple to use and dry quickly, leaving a pleasant feeling to the skin. Being inherently non-greasy and non-sticky means they can be worn comfortably under clothes without staining them.
Non-touch application
AKVANO® formulations allow non-touch application for sensitive skin. Non-touch application also minimises irritation for sensitive skin.
Reduced irritation
AKVANO® formulations do not require preservatives or additional components that may cause skin irritation. Furthermore, AKVANO® formulations reinforce the skin barrier function which render the skin less susceptible for irritation.
Increased patient compliance
The positive properties of AKVANO® mean it has the potential to increase compliance rates – leading to better efficacy outcomes, and increasing the willingness of physicians to prescribe the treatment to new patients.
Company
Lipidor is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in pre-clinical and clinical phases.
Lipidor update
It is an exciting and crucial period for Lipidor, as we are now approaching the publication of the results from our ongoing Phase III study.
During the second quarter 2024, we were able to announce that we had successfully completed a successful refinancing of the company with the aim of being able to conduct a new Phase III study of the updated drug candidate AKP02G2. The focus for the second half of 2024 has been to start the clinical study
Business scope
The global demand for pharmaceuticals for skin is a large and growing market. With the revolutionary AKVANO® delivery platform, Lipidor is at the cutting-edge of innovation. Want to know more?